RATIONALE AND OBJECTIVES: Phosphoethanolamine and phosphocholine, shown to be elevated in tumors and possibly related to apoptotic signaling, have the potential to be prognostic variables of cancer treatment. MATERIALS AND METHODS: The sum of phosphoethanolamine and phosphocholine normalized by nucleotide-triphosphates was determined in tumors of non-Hodgkin's lymphoma (NHL) patients via in vivo 31P MR spectroscopy. RESULTS: The normalized sum of phosphoethanolamine and phosphocholine showed significant differences in tumors of patients who had a complete response to treatment against those who did not (t-test: 1.45 +/- 0.15, mean +/- standard error, n = 10 vs. 2.28 +/- 0.15, n = 17, P < .001; Fisher test: P < .04; sensitivity and specificity approximately equal to 70%). This parameter also showed significant differences among treatment responses in the previously untreated and aggressive subgroups and in the low and low-intermediate-risk subgroups determined by the international prognostic index (IPI). Further, distinctly different treatment response cutoffs for the parameter were found in different risk groups. When these risk-dependent cutoffs were used, the Fisher test of the whole group improved (P < .0002, sensitivity 80%, specificity 94%). The normalized sum of phosphoethanolamine and phosphocholine and the IPI were better predictor covariates for time to treatment failure when fitted interactively in a Cox regression (P < .0003) than when fitted independently. When time to treatment failure was used as a surrogate of survival in Kaplan-Meier analysis, the interaction of both covariates segregated the cases significantly (P < .008). There was no significance with each covariate independently. CONCLUSION: The normalized sum of phosphoethanolamine and phosphocholine measured before treatment successfully predicts long-term response to treatment and time to treatment failure in non-Hodgkin's lymphoma, particularly when combined with the IPI.
RATIONALE AND OBJECTIVES:Phosphoethanolamine and phosphocholine, shown to be elevated in tumors and possibly related to apoptotic signaling, have the potential to be prognostic variables of cancer treatment. MATERIALS AND METHODS: The sum of phosphoethanolamine and phosphocholine normalized by nucleotide-triphosphates was determined in tumors of non-Hodgkin's lymphoma (NHL) patients via in vivo 31P MR spectroscopy. RESULTS: The normalized sum of phosphoethanolamine and phosphocholine showed significant differences in tumors of patients who had a complete response to treatment against those who did not (t-test: 1.45 +/- 0.15, mean +/- standard error, n = 10 vs. 2.28 +/- 0.15, n = 17, P < .001; Fisher test: P < .04; sensitivity and specificity approximately equal to 70%). This parameter also showed significant differences among treatment responses in the previously untreated and aggressive subgroups and in the low and low-intermediate-risk subgroups determined by the international prognostic index (IPI). Further, distinctly different treatment response cutoffs for the parameter were found in different risk groups. When these risk-dependent cutoffs were used, the Fisher test of the whole group improved (P < .0002, sensitivity 80%, specificity 94%). The normalized sum of phosphoethanolamine and phosphocholine and the IPI were better predictor covariates for time to treatment failure when fitted interactively in a Cox regression (P < .0003) than when fitted independently. When time to treatment failure was used as a surrogate of survival in Kaplan-Meier analysis, the interaction of both covariates segregated the cases significantly (P < .008). There was no significance with each covariate independently. CONCLUSION: The normalized sum of phosphoethanolamine and phosphocholine measured before treatment successfully predicts long-term response to treatment and time to treatment failure in non-Hodgkin's lymphoma, particularly when combined with the IPI.
Authors: Seung-Cheol Lee; Fernando Arias-Mendoza; Harish Poptani; E James Delikatny; Mariusz Wasik; Michal Marzec; Stephen J Schuster; Sunita D Nasta; Jakub Svoboda; Owen A O'Connor; Mitchell R Smith; Jerry D Glickson Journal: PET Clin Date: 2012-01
Authors: Ming Q Huang; David S Nelson; Stephen Pickup; Hui Qiao; E James Delikatny; Harish Poptani; Jerry D Glickson Journal: Acad Radiol Date: 2007-12 Impact factor: 3.173
Authors: Katja Pinker; Wolfgang Bogner; Stephan Gruber; Peter Brader; Siegfried Trattnig; Georgios Karanikas; Thomas H Helbich Journal: Breast Care (Basel) Date: 2011-04-29 Impact factor: 2.860
Authors: Eric A Mellon; Seung-Cheol Lee; Stephen Pickup; Sungheon Kim; Steven C Goldstein; Thomas F Floyd; Harish Poptani; E James Delikatny; Ravinder Reddy; Jerry D Glickson Journal: Magn Reson Med Date: 2009-12 Impact factor: 4.668
Authors: Fernando Arias-Mendoza; Geoffrey S Payne; Kristen Zakian; Marion Stubbs; Owen A O'Connor; Hamed Mojahed; Mitchell R Smith; Adam J Schwarz; Amita Shukla-Dave; Franklyn Howe; Harish Poptani; Seung-Cheol Lee; Ruth Pettengel; Steven J Schuster; David Cunningham; Arend Heerschap; Jerry D Glickson; John R Griffiths; Jason A Koutcher; Martin O Leach; Truman R Brown Journal: Acad Radiol Date: 2013-09 Impact factor: 3.173
Authors: D J Manton; A Chaturvedi; A Hubbard; M J Lind; M Lowry; A Maraveyas; M D Pickles; D J Tozer; L W Turnbull Journal: Br J Cancer Date: 2006-02-13 Impact factor: 7.640